Integrating New Developments in Initial Systemic Treatment in Biliary Tract Cancer Into Clinical Practice: A Spotlight on Immunotherapy

Watch this on-demand webcast of expert faculty presentation and case discussion on integrating immunotherapy for the initial systemic treatment of biliary tract cancer.

• Integrate guideline-concordant care into the individualization of therapy selection for patients with biliary tract cancer (BTC)

• Evaluate current and emerging evidence for use of immune checkpoint inhibitors in the initial and later-line treatment of patients with BTCs

• Identify patients eligible for enrollment in clinical trials of immune checkpoint inhibitors in the treatment of BTCs

• Apply guideline recommendations to identify and manage signs and symptoms of irAEs in patients treated with immune checkpoint inhibitors for BTC

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-24-300-H01-P 

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until April 28, 2025. PAs should only claim credit commensurate with the extent of their participation.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

The planners and content peer reviewers from Clinical Care Options, LLC, do not have any relevant financial relationships to disclose, except ​Kristi K. Orbaugh, MSN, NP, AOCNP, as noted below.​

Kristi K. Orbaugh, MSN, NP, AOCNP: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Daichii Sankyo, Eli Lilly, Gilead, Pfizer, Regeneron, SOBI.